Hepatic Cirrhosis Market Size, Epidemiology, Trends, and Forecast 2025-2035

 The 7 major hepatic cirrhosis markets reached a value of USD 3.2 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 5.0 Billion by 2035, exhibiting a growth rate (CAGR) of 4.06% during 2025-2035.

The global burden caused by cirrhosis of the liver is worrying as it can stem from more than one cause. Hepatic cirrhosis, which is the serious scarring of liver tissue owing to chronic liver disease, is considered as one of the main issues for several healthcare systems across the globe. Strikingly, the predicted figures for the cirrhosis treatment market in 2025 seem quite optimistic, primarily attributed to medical innovations coupled with transformational disease patterns.    

There's no denying that liver cirrhosis as a disease has a tangible impact on human life. The post-market cirrhosis treatment for 2025 is bound to see changes attributing to the recently rising consumption of alcohol and the due increase in NAFLD owing to diabetes. With an increase of 5-7% each year the market for hepatic cirrhosis treatment stands on a good position even in developing countries. These are believed to face an increase in hepatitis B and C infections owing to the lack of preventive healthcare measures.

Changes In Treatment Strategies  

The existing treatment frameworks are mostly concentrating on controlling complications while trying to appease the progression of the disease. However, steps in the right direction seems to terminally be shifting with:  

Clinical testing indicates promise with antifibrotic medications like FXR agonists (ombeticholic acid) and newer PPAR agonists for reducing liver scarring. Some researchers are also advancing with speculative stem cell therapies that might one day be capable of restoring the division tissue of the liver.  

For patients suffering from advanced cirrhosis, liver transplantation forever remains as the definitive solution. There has been little progress in obtaining slots however, which has catalyzed new organ preservation techniques like machine perfusion systems that enhance the duration within which donor livers can be used. Other Artificial liver support devices are also vastly improving, stabilizing critically sick patients until they can receieve the transplant.  

New Diagnoses Techniques   

Cirrhosis diagnosis is often seen as being invasive and with the advancement of non-invasive techniques, there has been a reinvention in how cirrhosis is diagnosed and assessed:  

Elastography FibroScan methods measure liver stiffness accurately without the need of surgically obtaining a sample. In addition, there are newer panel biomarkers that assist clinicians in precisely gauging the stage of fibrosis. Even more impressively, medical imaging and AI combined allows for earlier and far more precise detection of liver damage patterns that were likely to be ignored by the human eye.

Request for a sample of this report: https://www.imarcgroup.com/hepatic-cirrhosis-market/requestsample

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hepatic cirrhosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hepatic cirrhosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current hepatic cirrhosis market drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the hepatic cirrhosis market has been studied in the report with the detailed profiles of the key players operating in the market.

1. AstraZeneca

2. Lipocine Inc.

3. Rohto Pharmaceutical

4. Prism Pharma

Bristol-Myers Squibb

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=20108&flag=A

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145